CJC-1295 with DAC lasts for days in the body, while the version without DAC clears in about 30 minutes. Compare half-life, dosing, and side effects.
CJC-1295 with DAC and CJC-1295 without DAC are the same growth hormone-releasing hormone (GHRH) analog, and the main difference between them is the Drug Affinity Complex. That added group lets the with-DAC version bind to albumin in the bloodstream and stay active for roughly six to eight days, while the version without DAC keeps a half-life of about 30 minutes. It is the same core peptide with a very different duration in the body.
What Is CJC-1295?
CJC-1295 is a synthetic peptide modeled on GHRH, the hormone the hypothalamus releases to signal the pituitary gland to make growth hormone. It is built from GHRH(1-29), the shortest piece of the natural hormone that still triggers growth hormone release.
Four amino acids in that fragment are swapped out so the peptide resists DPP-4, the enzyme that normally breaks down GHRH within minutes. If you are still asking what is cjc 1295 peptide, the plain answer is that it is a lab-made analog that prompts the pituitary to release the body's own growth hormone rather than supplying growth hormone directly.
CJC-1295 is not FDA-approved for human use in the United States. It is sold as a research chemical, which means no regulator reviews its purity, dosing, or safety.
CJC-1295 With DAC: The Long-Acting Version
DAC stands for Drug Affinity Complex. It is a maleimide group attached to the peptide that forms a strong bond with albumin, the most abundant protein in blood plasma. Albumin works like a slow-release carrier, so the peptide stays in circulation far longer than an unmodified peptide would.
Pharmacokinetic studies put the half-life of CJC-1295 with DAC at roughly six to eight days. In practical terms, one injection keeps growth hormone and IGF-1 levels elevated for most of a week.
That steady elevation is often called GH bleed, because it replaces the body's natural bursts of growth hormone with a continuous signal. Whether that pattern is helpful or harmful is still an open question in the research literature.
- Injection frequency: once or twice per week in most research protocols
- Common research doses: 1 to 2 mg per week, sometimes split into two injections
- Most common vial sizes: 2 mg and 5 mg of lyophilized powder
- Growth hormone pattern: sustained rather than pulsatile
Vials labeled cjc-1295 with dac 5mg hold 5 milligrams of powder that must be reconstituted with bacteriostatic water before use.
CJC-1295 Without DAC: The Short-Acting Version
CJC-1295 without DAC is the same modified GHRH(1-29) fragment minus the albumin-binding group. It usually appears on labels as Mod GRF(1-29), Modified GRF 1-29, or tetra-substituted GRF(1-29).
Its half-life is roughly 30 minutes. That short window matches the way the body naturally releases growth hormone, in distinct pulses instead of a constant drip. Because it clears so quickly, it is almost always paired with a growth hormone-releasing peptide such as ipamorelin or GHRP-2 to amplify each pulse.
CJC-1295 With DAC vs Without DAC: Side-by-Side
The table below summarizes the practical differences researchers look at when choosing between the two forms.
| Feature | CJC-1295 With DAC | CJC-1295 Without DAC |
|---|---|---|
| Other names | DAC:GRF, CJC-1295 DAC | Mod GRF(1-29), Modified GRF 1-29 |
| Half-life | About 6 to 8 days | About 30 minutes |
| GH release pattern | Continuous elevation | Pulsatile bursts |
| Typical research dose | 1 to 2 mg per week | 100 mcg, one to three times daily |
| Injection frequency | Once or twice weekly | Daily |
| IGF-1 effect | Sustained elevation | Short, pulse-driven rise |
| Albumin binding | Yes | No |
How These Peptides Are Used in Research
Protocol design usually comes down to one question: does the study want a long, flat signal or a sharp, natural pulse? Work focused on pulsatile growth hormone release tends to use the version without DAC, stacked with a GHRP.
That is why discussions of cjc-1295 ipamorelin with dac or without come up so often. Ipamorelin triggers a growth hormone pulse through a different receptor, and combining it with Mod GRF(1-29) mimics the body's two-signal system for growth hormone release.
The wider question of what is cjc-1295 ipamorelin used for usually points to body composition, recovery, and sleep quality in research and self-experimentation circles. None of those uses has been confirmed in large human clinical trials.
Side Effects and Safety Considerations
Reported side effects for both versions include injection-site irritation, flushing, headache, dizziness, nausea, and increased appetite. Water retention and joint discomfort also come up often, most likely tied to higher growth hormone and IGF-1 levels.
The version with DAC raises an extra concern, because IGF-1 stays elevated for days at a time. There is no long-term human safety data for CJC-1295. Anyone weighing these peptides should talk with a licensed healthcare professional first, and people who are pregnant, nursing, or being treated for cancer should avoid growth hormone secretagogues entirely.
Labels, Vials, and Marketing Confusion
Product naming in this space is inconsistent, so the molecular name matters more than the brand printed on the vial.
- A vial labeled simply CJC-1295 is often, but not always, the DAC version.
- Mod GRF, Modified GRF 1-29, and DAC-free all refer to the short-acting peptide.
- Some vendors sell both forms side by side and label them loosely.
Photos and logs tagged cjc 1295 with dac before and after are easy to find online, but they are anecdotal and frequently posted by sellers. Treat before-and-after claims as marketing rather than evidence.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
The only structural difference is the Drug Affinity Complex, a maleimide group that binds the peptide to albumin in the blood. That binding stretches the half-life from about 30 minutes for the version without DAC to roughly six to eight days for the version with DAC. The longer half-life produces a continuous rise in growth hormone and IGF-1 instead of natural pulses.
How long does CJC-1295 with DAC stay in your system?
With a half-life of roughly six to eight days, a single dose of CJC-1295 with DAC can take about a month to clear completely from the body. Toward the end of that window the remaining amount is small, but the effect on IGF-1 can linger. The version without DAC is largely gone within a few hours.
Is CJC-1295 FDA-approved?
No. CJC-1295 is not FDA-approved for human use in the United States, and it is not a scheduled controlled substance either. It is sold as a research chemical, which means the FDA does not evaluate it for purity, dosing, or safety. Anyone considering it should speak with a licensed healthcare professional.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.